QCG
ARQT icon

Quadrant Capital Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Quadrant Capital Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,550
Closed -$36.5K – 1338
2026
Q1 		$36.5K Hold
1,550
– – ﹤0.01% 1802
2025
Q4 		$45K Hold
1,550
– – ﹤0.01% 1724
2025
Q3 		$29.2K Buy
+1,550
New +$24.4K ﹤0.01% 1830
2025
Q2 		– Sell
-1,550
Closed -$24.2K – 1418
2025
Q1 		$24.2K Hold
1,550
– – ﹤0.01% 1982
2024
Q4 		$21.6K Hold
1,550
– – ﹤0.01% 1856
2024
Q3 		$14.4K Hold
1,550
– – ﹤0.01% 2029
2024
Q2 		$14.4K Sell
1,550
-326
-17% -$2.95K ﹤0.01% 1988
2024
Q1 		$18.6K Buy
+1,876
New +$14K ﹤0.01% 1878
2023
Q4 		– Sell
-936
Closed -$4.97K – 2698
2023
Q3 		$4.97K Buy
936
+875
+1,434% +$7.44K ﹤0.01% 2177
2023
Q2 		$582 Buy
+61
New +$677 ﹤0.01% 2554

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quadrant Capital Group's ARQT Position: Q2 2026 in Review

Quadrant Capital Group sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 1,550 shares — an estimated $36.5K sold.

Quadrant Capital Group first reported a position in ARQT in Q2 2023 and held it in 10 quarters. The position peaked at $45K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Quadrant Capital Group reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 1,550 Arcutis Biotherapeutics shares in Q2 2026, an estimated $36.5K.
  • Quadrant Capital Group first reported a position in Arcutis Biotherapeutics in Q2 2023 and held it in 10 quarters.
  • Quadrant Capital Group's Arcutis Biotherapeutics position peaked at $45K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.